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Brain-derived neurotrophic factor (BDNF) is a neurotrophin with functions related to neuronal survival/proliferation processes
and inﬂammation. BDNF is also an important central pain mediator. The levels of BDNF have been found to be high for RA
patients with severe disease and to become lowered in response to anti-TNF treatment. New information says that the levels of
BDNF in the blood parallel the BDNF concentrations in the brain and that BDNF can pass the blood-brain barrier. Furthermore,
most of the circulating BDNF is produced in the brain. Habitual and regular exercise, in contrast to temporary exercise, does
also lead to a lowering of BDNF blood levels. Both anti-TNF treatment and habitual and regular exercise do have pain-relieving
eﬀects. Itmightbe thatthepain-relieving eﬀect ofanti-TNF treatment isrelated to an aﬀection of central neuronal regions, hereby
inﬂuencing BDNF production. Measurements of BDNF in the blood help us to clarify the magnitude of centrally related pain for
RA patients and help us to explain the relief of this pain in response to anti-TNF treatment.
1.Background
Measurements of factors in blood are regularly being
undertaken for patients with rheumatoid arthritis (RA).
Then comes the interpretation of the signiﬁcance of the
values obtained. One factor for which the levels were found
to be higher for patients with severe RA than for controls,
and for which the levels were found to be decreased in
response to anti-TNF treatment, is the neurotrophin brain
derived neurotrophic factor (BDNF) [1]. The signiﬁcance
of this observation has been unclear. However, based on
the fact that BDNF is a central pain mediator and based on
information obtained during the last 2 years concerning the
interrelationship between the blood levels of BDNF and the
concentrations of BDNF in the brain a new understanding
is under way. An understanding that most of the circulating
BDNF originates in the brain is also of importance. The new
information obtained can help us to better understand the
BDNF blood levels in relation to marked pain for patients
with severe RA and the pain-relieving eﬀect of anti-TNF
treatment.
2.General AspectsonNeurotrophins
Neurotrophinsconstituteaclassofgrowthfactors comprised
by nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), neutrophin 3 (NT-3), and neurotrophin 4
(NT-4) [2]. The most frequently studied neurotrophins are
NGF and BDNF. The neurotrophins are initially synthesized
as proneurotrophins that later are cleaved to their mature
forms. They bind to two types of receptors, the high-aﬃnity
tyrosine kinase receptors (TrkA, TrkB, and TrkC) and the2 International Journal of Inﬂammation
low-aﬃnity neurotrophin receptor p75 (NGFR-p75). The
high aﬃnity receptors bind the neurotrophins with diﬀerent
aﬃnity, NGF binding to TrkA, BDNF and NT-4/5 binding
to TrkB, and NT-3 binding to TrkC, whilst the low-aﬃnity
receptor NGFR-p75 binds all neurotrophins with similar
aﬃnity [3–5].
Synthesis of neurotrophins occurs particularly in neu-
ronsandinﬂammatory cells,andalsoinothercelltypes.That
includes keratinocytes, epithelial cells and cells within the
connective tissue and skeletal muscle [6]. A cell type recently
observedto show expression ofneurotrophinsisthetenocyte
of Achilles tendons [7].
3.FunctionalAspectsforNeurotrophins
The neurotrophins promote the survival of neurons [8, 9]
and are important for cell proliferation [10]a n di n ﬂ a m -
matory processes [11]. Following nerve injury, there is an
upregulation of neurotrophin expression [12]. There is often
an overexpression of neurotrophins during inﬂammation
processes [11], and neurotrophin receptors are, for example,
overexpressed in human airways infected with respiratory
syncytial virus [13]. In studies on ulcerative colitis, it was
found that there was an upregulation concerning neuro-
trophins for the lamina propria cells, these mainly conform-
ing to inﬂammatory cells, whilst there was a downregulation
in expression for these in the nerve structures [14].
Observations made in studies on the development of
insulitis for the nonobese diabetic (NOD) mouse, a model
for type 1 diabetes, suggested that there are attempts by
neurotrophins to promote nerve ingrowth and survival of
the pancreatic islets in this situation [15]. It is argued that
the increased expressions of neurotrophins that occur in
brain lesions [16] and gut inﬂammation [17] are related
to neuroprotective roles. Overexpressions of neurotrophins
may actually be involved in the modulation rather than the
induction of inﬂammatory responses [18]. The neurotro-
phins can on the whole fulﬁll a link between the nervous and
immune systems.
Neurotrophins do also have apoptosis-modifying func-
tions[19].Neurotrophinscanhaveanimportanceinrelation
to pain sensations as well [20], including the pain that is
associated with inﬂammation [21].
4.F ocusonB D N FintheP r esen tR eview
Focus is in the present paper directed towards BDNF. Recent
data obtained do, as described above, thus favour that it is
indeedofrelevancetofocusonBDNFconcerningRA.BDNF
has been considered to have a role as a major contributor
to inﬂammatory pain and to on the whole be a central
pain modulator [22]. BDNF has actions at central synapses
in pain pathways [20] and is upregulated in the dorsal
horn following peripheral inﬂammation [23]. It is suggested
that the BDNF/TrkB system may for example contribute
to persistent pain after tooth repair [24]. Interesting obser-
vations on the interplay between the brain and peripheral
bloodBDNFconcentrationshavebeendocumentedinrecent
studies.
5.Importance ofBDNF forJoints,
IncludinginArthritis
It has long been argued that neurotrophins may be involved
in arthritic processes [25, 26]. That was primarily suggested
to be the fact for NGF. Evidence which favoured such a
suggestion were the ﬁndings of increased levels of NGF in
synovial ﬂuid [25, 27] and peripheral blood [28, 29]f o r
patients with chronic arthritis, spondylarthropathy, and RA.
An upregulationofNGFin mononuclearcells inﬁltrating the
inﬂamed synovium and an increase in synovial nerve ﬁbers
expressing NGFR-p75 were also noted in studies on the rat
[30]. Evidence which suggested that NGF might have a role
in thehealingphase ofjointinﬂammation was also presented
[18].
More recently, research has been performed concerning
BDNF and human synovium and arthritis. The existing
information says that BDNF is produced locally in synovial
tissue, that BDNF mRNA can be detected in the inﬂam-
matory synovium of RA patients [31] and that there are
BDNF immunoreactions for macrophages and ﬁbroblasts in
the human synovial tissue [32]. There is BDNF expression
in neurons supplying the synovial tissue as well, and
immunoreactions for both NGFR-p75 and TrkB, to which
receptors BDNF bind, occur for nerve fascicles and for
strands located within lymphoid aggregates in the human
synovial tissue [1]. NGFR-p75 reactions are also present in
association with the blood vessels [1]. As both TrkB and
NGFR-p75 immunoreactions are detectable in the human
synovial tissue, it is presumable that BDNF has local eﬀects
via having interactions with these receptors. An important
function for BDNF locally in the synovial tissue may not
least be related to inﬂuences on the nerve structures. Such a
suggestion is in line with the known fact that neurotrophins,
as discussed above, show survival-promoting, healing, and
protective eﬀects forneurons.
In studies on a mouse model of arthritis that is similar to
thecollagen-inducedarthritismodel,namely,localinjection-
induced arthritis [33], marked expressions for NGF and
BDNF, as well as their receptors, could be seen in the inﬂam-
matory inﬁltrates of the arthritis animals [34]. Expressions
of NGF/BDNF and the neurotrophin receptors were also
seen in the articular chondrocytes lining the joint cavities.
However, reduced neurotrophin receptor immunoreactions
in chondrocytes were seen for severely arthritic animals [34].
Expressions of NGFR-p75 and TrkA, as well as NGF, have
also been noted for human articular chondrocytes [35, 36].
The ﬁndings concerning the lining cartilage in the mouse
model suggest that neurotrophins are of importance for the
cartilage lining the joint cavity having autocrine/paracrine
eﬀectsand thatthedecreaseinexpression levelsoftheneuro-
trophin receptors seen in severe arthritis can be a drawback
for cartilage function.
BDNF has been found to be measurable in the synovial
ﬂuid in only a subpopulation of RA patients [1, 32]. It is
thus possible that leakage of BDNF into the synovial ﬂuid
only occurs to a small extent for RA patients and that BDNF
mainly becomes bound to its receptors in the synovium orInternational Journal of Inﬂammation 3
the lining cartilage instead of being released into the synovial
ﬂuid.
6.B D N FCanBeA n aly s edinB lood
BDNF can be measured in plasma as well as in serum. Inter-
esting observations have been made in this regard during re-
cent years. This means that it has been found worthwhile to
analyse for BDNF blood levels.
The blood levelsofBDNFhavebeen found to be elevated
in several conditions, however, not all. There are increased
blood levels of BDNF in patients with ﬁbromyalgia [37, 38]
and atopic dermatitis [39]. The blood levels of BDNF are
also found to be signiﬁcantly higher during a migraine
attack than in pain-free periods [40]. Patients with multiple
sclerosis show higher BDNF levels in the blood than healthy
controls [41]. On the other hand, the BDNF levels in the
blood were found to be lower for patients with early stage
glaucoma than for control subjects [42].
It is frequently documented that the serum levels of
BDNF are decreased in major depressive disorders [43, 44].
There isalso evidencewhich favours thatBDNFmay actually
play an important role in the pathogenesis of these disorders
[45] and that BDNF signaling may also contribute to the
pathogenesis of schizophrenia [46]. Adults with epilepsy
are reported to have decreased levels of serum BDNF
[47].
7.BDNF Blood LevelsinRelationto
Severityof Diseases
A relationship between disease severity and BDNF levels has
been noted for certain situations. There is a lowering of the
BDNFplasma levels with increasing severity of depression in
patients with mood disorders [48]; that is, there is a negative
correlation between BDNF blood levels and the severity
of depression [43]. An increase in BDNF levels has been
seen for psychotic patients that have been treated with the
antipsychotic olanzapine but not other tested antipsychotics
[49]. The serum BDNF level is reported to be a biological
marker for the severity of psychiatric symptoms in patients
with neuropsychiatric systemic lupus erythematosus [50].
It is described that there is a relationship between serum
BDNF levels, but not serum NGF levels, and disease severity
in atopicdermatitis[51].Ithas also been shown thatsubjects
with moderate or severe asthma have higher BDNF levels in
plasma than patients with mild asthma and controls [52].
M¨ uller and collaborators [52] suggest that BDNF might be
a potential biomarker for clinical severity for children with
asthma.
It has been shown that plasma BDNF signiﬁcantly
correlates with multiple risk factors for metabolic syndrome
and cardiovascular function [53]. Accordingly, increased
levels of cardiorespiratory ﬁtness and habitual exercise are
associated with lower resting levels of serum BDNF levels
in healthy humans [54]. Also, in another study, it was
considered that the BDNF blood levels correlate with risk
factors for metabolic syndrome [55].
8.Inﬂuence ofPhysical Activityon
Brain andPeripheralBlood BDNF
Physicalexerciseenhancesthemoodandcognitivefunctions,
increases the expression of BDNFin the brain and can short-
term increase plasma and serum BDNF concentrations in
humans [56]. Knaepen and collaborators [57]h a v ew r i t t e n
a comprehensive review concerning the aspects of exercise-
induced responses of BDNF. It was concluded that in the
majority of studies performed, there was a transient increase
in plasma or serum BDNF concentration following an acute
aerobic exercise. Resistance exercise induces a robust but
transient elevation of circulating BDNF [58]. That includes
thesituationforpersonswithmajordepression[59].Exercise
is shown to have eﬀects in the brain via activation of the
BDNF-TrkB signaling pathway [60].
However, it is important to note that the situation is
diﬀerent for persons who experience habitual exercise, than
those who train irregularly. Recreational male runners have
thus lower serum levels of BDNF than matched control
individuals [61], indicating a downregulation of BDNF with
marked habitual exercise. Also the study by Currie and
collaborators [54] show this fact (c.f. above).
9.ComparisonsbetweenBrain and
PeripheralBloodBDNFLevels
It has recently been shown that measures of serum and
plasma BDNF levels reﬂect brain-tissue levels across species
[62].Itisalsoshownthatinparallelwiththeoccurrenceofan
increased BDNF expression in the hippocampus in response
to endurance training, there is an enhanced release into the
blood from the brain [63]. It is obvious that BDNF can cross
the blood-brain barrier [64], there being a release of BDNF
from the brain tothe blood [65].BDNFinthe bloodcanalso
be retrogradely transported to the brain, hereby crossing the
blood-brain barrier.
The circulating BDNF is known to originate both from
the brain and from peripheral sources. It is considered
that the brain constitutes almost 75% of the circulating
BDNF [65]. The peripheral sources are constituted by a large
number of cell types [57].
10.BDNF inBlood inResponse to Anti-TNF
TreatmentforRAPatients
Instudiesonthebloodlevels(plasma)ofBDNF,theeﬀectsof
a TNF-blocker(inﬂiximab) were examined in ourlaboratory
[1]. Plasma of 18 patients with RA who had failed on disease
modifying antirheumatic drugs were examined. Inﬂiximab
(3mg/kg body weight) was given as intravenous infusion
according to recommendations, at baseline, and at 2weeks,
6weeks, and thereafter every 8weeks. Seventeen of the
patientshadalsobeentreatedwithmethorexate.Itwasfound
that the BDNF level before the anti-TNF treatment was 4
600pg/ml (median) and (Q1–Q3) 3 700 to 7 600pg/ml.
There was a trend towards a decrease after 2h after the initial
treatment. At examination 14weeks after starting treatment,4 International Journal of Inﬂammation
the levels of BDNF had decreased signiﬁcantly. There was no
signiﬁcant diﬀerence between the levels of BDNF found for
14weeks samples and 30weeks samples. The baseline level
was higher than that for healthy controls.
The ﬁnding that anti-TNF treatment leads to a decrease
in BDNF levels is partly in line with observations made in
a previous preliminary report [66]. In that study, it was
described that the plasma levels of BDNF decreased, but
not signiﬁcantly, in response to this treatment. It is obvious
that anti-TNF treatment can have an inﬂuence on the BDNF
levels. This is an interesting aspect and an aspect that has not
previouslybeenconsideredwhendiscussingtheeﬀectsofthis
treatment.
11.InterplaybetweenBDNF andTNFalpha;
Relationto Pain
It has previously been noted that TNFalpha enhances the
secretion of BDNF from circulating human monocytes [67].
However, it is not obvious that anti-TNF treatment has its
eﬀect on inﬂammatory related BDNF. The levels of BDNF in
plasma after anti-TNF treatment thus did not correlate with
inﬂammatory parameters, nor were there any correlations
between levels of BDNF in synovial tissue and the number
of inﬂammatory cells observed microscopically [1].
Based on our ﬁndings of BDNF/TrkB immunoreactions
in nerve structures in the synovial tissue, recent ﬁndings of
interrelationships between TNFalpha/BDNF-BDNF recep-
tors for nerve structures are noteworthy. In studies using
a rat model of herniated nucleus pulposus in relation to
spinal cord damage, it has thus been shown that inﬂiximab
appears to prevent hyperalgesia [68] and that this treatment
attenuates the BDNF levels in the dorsal root ganglion and
spinal cord [69].
Based on the new information described above, it is
obvious that the blood levels of BDNF correlate with the
brain levels of this neurotrophin, that BDNF passes the
blood-brain barrier, and that as much as 75% of the BDNF
is actually originating from the brain. It is also obvious
that there is a similarity between the eﬀects that anti-TNF
treatment and habitual and regular exercise have on blood
levels of BDNF, the levels becoming decreased in both cases.
Thatshouldmeanthatthebrainlevelsareloweredaswell.So,
it can be hypothesized that the pain relief that the anti-TNF
treatment has can be related to a downregulation of BDNF
brain(andsecondarilyblood)levels.BDNFis,ascommented
on above, recognized as an important central pain mediator.
A lowering of brain BDNF levels should therefore be a
favourable situation. It is a well-known fact that regular
physicalactivity andexercise,if itcanbeperformed, canhave
pain-relieving eﬀects for persons with RA.
It should here be recalled that it has long been asked
how anti-TNF treatment achieves the rapid pain relief that
can occur. A new study favouring that neutralization of
TNFalpha indeed has eﬀects on nociceptive brain activity
is therefore very interesting. Via the use of functional MRI,
it was thus shown that nociceptive CNS activity in several
brain regions were blocked after infusion of a monoclonal
antibody to TNFalpha at early time points, that is, at time
points at which joint swelling and acute phase reactants were
not aﬀected [70].
12.ConcludingRemarks
The existing information says that:
(1) BDNF levels can easily be analysed in both plasma
and serum.
(2) The blood levels of BDNF in patients with severe RA
are elevated as compared to controls and these levels
are decreased in response to anti-TNF treatment.
(3) BDNF is an important factor to analyse for in RA as
it is related to pain symptoms and as the BDNF/TrkB
system is likely to be of signiﬁcant importance for
the inﬂammation and the nerve structures in the
synovium and for the lining cartilage of joints. Even
moreimportantisthefactthatBDNFisacentralpain
mediator.
(4) There are correlations between brain and blood
BDNF levels. Most of the BDNF we analyse in the
blood comes from the brain.
(5) The situation with a downregulation of the BDNF
levels in response to anti-TNF treatment is compa-
rable with the situation seen for persons exhibiting
regular and habitual exercise. Temporary exercise
leads instead short-term to an increased level of
BDNF in the blood.
(6) A new understanding of the relationship between
BDNF and TNFalpha has been achieved. Measure-
ments of BDNF in the blood can thus help us to
clarify the magnitude of centrally related pain for RA
patients and help us to explain the relief of this pain
in response to anti-TNF treatment.
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